Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
MY TRIALS
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Register a trial
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT03179423
Registration number
NCT03179423
Ethics application status
Date submitted
1/06/2017
Date registered
7/06/2017
Titles & IDs
Public title
Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
Query!
Scientific title
Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years
Query!
Secondary ID [1]
0
0
GNC-301
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RAINBOW-T1D
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes Mellitus Type 1
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GNbAC1
Treatment: Drugs - Placebo
Experimental: GNbAC1 - Monthly IV repeated dose
Placebo comparator: Placebo - Monthly IV repeated dose
Treatment: Drugs: GNbAC1
Monthly IV repeated dose
Treatment: Drugs: Placebo
Monthly IV repeated dose
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety and tolerability of GNbAC1 in patients with recent onset type 1 diabetes: Serious Adverse Events (SAE) and Adverse Events (AE)
Query!
Assessment method [1]
0
0
Serious Adverse Events (SAE) and Adverse Events (AE)
Query!
Timepoint [1]
0
0
Week 1 to 24/48
Query!
Eligibility
Key inclusion criteria
Main
* Subjects diagnosed with type 1 diabetes in the 4 years prior to signed informed consent;
* Peak stimulated C-peptide of =0.2 nmol/L during a mixed meal tolerance test performed during the Screening period;
* 18 to 55 years of age (both inclusive);
* Body weight >40 to =100 kg;
* Subjects positive for at least one diabetes-associated autoantibody (insulin, glutaminic-acid-decarboxylase-65 [GAD-65], tyrosine phosphatase-related antigen 2 [IA-2], ZnT8 or islet-cell antibody [ICA]).
Main
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
55
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Subjects with type 2 diabetes;
* Pregnant and nursing women.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/06/2017
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
7/05/2019
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
64
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Macquarie University Hospital - Macquarie University
Query!
Recruitment hospital [2]
0
0
AIM Centre - Merewether
Query!
Recruitment hospital [3]
0
0
Northern Sydney Local Health District - Royal North Shore Hospital - St Leonards
Query!
Recruitment hospital [4]
0
0
Ipswich Research Centre - Ipswich
Query!
Recruitment hospital [5]
0
0
Mater Misericordiae Ltd and Mater Medical Research Institute Limited - South Brisbane
Query!
Recruitment hospital [6]
0
0
Gold Coast Hospital and Health Service - Southport
Query!
Recruitment hospital [7]
0
0
Southern Adelaide Local Health Network - Repatriation General Hospital - Adelaide
Query!
Recruitment hospital [8]
0
0
Northern Adelaide Local Health Network Incorporated, operating as Lyell McEwin Hospital - Elizabeth Vale
Query!
Recruitment hospital [9]
0
0
Eastern Health - Box Hill
Query!
Recruitment hospital [10]
0
0
St Vincent's Hospital (Melbourne) Limited - Fitzroy
Query!
Recruitment hospital [11]
0
0
Barwon Health - University of Geelong - Geelong
Query!
Recruitment hospital [12]
0
0
Heidelberg Repatriation Hospital - Heidelberg
Query!
Recruitment hospital [13]
0
0
Keogh Institute of Medical Research - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
- Macquarie University
Query!
Recruitment postcode(s) [2]
0
0
- Merewether
Query!
Recruitment postcode(s) [3]
0
0
- St Leonards
Query!
Recruitment postcode(s) [4]
0
0
- Ipswich
Query!
Recruitment postcode(s) [5]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [6]
0
0
- Southport
Query!
Recruitment postcode(s) [7]
0
0
- Adelaide
Query!
Recruitment postcode(s) [8]
0
0
- Elizabeth Vale
Query!
Recruitment postcode(s) [9]
0
0
- Box Hill
Query!
Recruitment postcode(s) [10]
0
0
- Fitzroy
Query!
Recruitment postcode(s) [11]
0
0
- Geelong
Query!
Recruitment postcode(s) [12]
0
0
- Heidelberg
Query!
Recruitment postcode(s) [13]
0
0
- Nedlands
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GeNeuro Australia PTY Ltd
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Southern Star Research Pty Ltd.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous Multiple Sclerosis associated RetroVirus (MSRV), which could play a critical role in different autoimmune disorders, notably type 1 diabetes (T1D). This study is a multicentre study evaluating for the first time the safety and efficacy of GNbAC1 in T1D subjects for a first bouble-blind period of 20 weeks followed by an optional open-label period of 24 weeks. The primary objective of the study is to assess the safety and tolerability of six consecutive 4-weekly doses of GNbAC1 in subjects with T1D. Secondary objectives are to determine the pharmacodynamic response to GNbAC1 on biomarkers of T1D.
Query!
Trial website
https://clinicaltrials.gov/study/NCT03179423
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT03179423